IPEC Federation publishes Position Paper on Supply Chain Security for Pharmaceutical Grade Excipients
Brussels, 23 May 2019
The IPEC Federation has published a new position paper on Supply Chain Security for Pharmaceutical Grade Excipients on 23 May 2019.
Supply chain security requires the protection and control of pharmaceutical excipients across the entire supply chain, downstream from the excipient manufacturer to the finished dosage form producer. Throughout, product quality, traceability and integrity must be assured in order to minimize the risk to patients which may result from the use of falsified and sub-standard excipient products.
This paper was written in response to many tragedies, even deaths, caused by the use of falsified excipients in recent decades. Today’s increasingly complex global supply chains create additional risk and therefore considerations related to excipient security.
Aimed at providing support to all parties involved in the supply chain, for example pharmaceutical excipient manufacturers, distributors (re-packers, bulk storage and packed storage warehouse providers), traders, brokers, carriers and other service providers, the paper summarizes existing applicable regulations and various tools supporting good practices for supply chain security and ultimately drug safety. These include IPEC Federation’s Good Distribution Practices Guide for Pharmaceutical Excipients, IPEC-Americas Risk Assessment Guide and the EXCiPACT and NSF/IPEC/ANSI 363 certifiable GMP and GDP standards for excipient suppliers.
The IPEC Federation specifically emphasises that while overall responsibility remains with the finished dosage form manufacturer, each participant in the supply chain, both up and downstream, has responsibilities for its own specific area of activity. Establishing controls at each interface is imperative, where the level of control required can be determined using IPEC’s Risk Assessment Guides. These principles should establish and ensure supply chain security of excipients thereby minimising risk to patients.
For further information please contact email@example.com or +32 2 2137440.